InSilico Medicine Appoints Former FDA CDER Director and Amgen R&D Executive Steven Galson as Independent Director

HONG KONG, Aug. 11, 2021 /PR Newswire/ -- InSilico Medicine, an industry-leading AI-driven drug discovery company, announced the appointment of Dr. Steven Galson as an Independent Director of the Board.

Dr. Steven Galson stated, “The success of drug development depends on improving both the speed and success rate of R&D, and artificial intelligence provides a guarantee for both. I am honored to be part of InSilico Medicine, a pioneering force leading this cutting-edge field.”

Steven Galson, MD, MPH. He served as a senior research and development executive at the California-based biopharmaceutical company Amgen for over a decade, during which he led global regulatory affairs and drug safety, and recently retired from the company. He also served as a Distinguished Professor at the Keck Graduate Institute (KGI) in Claremont, California. From October 1, 2007, to October 1, 2009, he served as the Surgeon General of the U.S. Public Health Service Commissioned Corps, holding the rank of retired Rear Admiral and serving as Commander of the Commissioned Corps. Concurrently, from January 22, 2009, to June 25, 2009, he served as the Assistant Secretary for Health, acting as the operational head of the Public Health Service. From 2001 to 2007, he served as Deputy Director and Director of the Center for Drug Evaluation and Research (CDER) at the U.S. Food and Drug Administration (FDA).

Dr. Alex Zhavoronkov, Founder and Chief Executive Officer of InSilico Medicine, stated, “Dr. Steven Galson is one of the most respected biopharmaceutical executives and public health physicians in the world, dedicated to delivering effective medicines to patients globally faster, more affordably, and more safely. He is also an expert in regulatory affairs and understands the importance of disruptive innovation at every stage of research and development. We are deeply honored to have Dr. Galson join our Board of Directors.”

This July, InSilico Medicine announced the completion of a $255 million financing round led by Warburg Pincus, which attracted participation from over 25 prominent investors. In August, the company announced its second preclinical candidate for renal fibrosis.